top of page
Search

Another addition to kidney disease prevention

Semaglutide reduced the risk of clinically important kidney outcomes and death from cardiovascular causes in patients with type 2 diabetes and chronic kidney disease. 



Based on pleitropic effects of GLP-1 agonists as a drug class, the results are not surprising and serve as a welcome addition to the armamentarium of ever increasing diabetic kidney disease drugs 


 
 
 

Recent Posts

See All
Residency education funding

How about shifting the reliance on medicare funding for GME (residency/fellowship) to private inititiaves such as hospital funded...

 
 
 
Xeno-transplanted kidney

eGenesis, a biotech company based out of Cambridge, MA along with a group of surgeon/physician scientists at Massachusetts General...

 
 
 
Metformin or not

Should Metformin remain as the first line agent for oral treatment of T2DM?  NYTimes piece sheds some light on how Metformin is being...

 
 
 

Comments

bottom of page